-+ 0.00%
-+ 0.00%
-+ 0.00%

Aptevo reports 86% clinical benefit rate and 0% CRS for mipletamig plus venetoclax and azacitidine in frontline AML trial data

Reuters·03/11/2026 10:01:44

Please log in to view news